251 related articles for article (PubMed ID: 34697882)
1. A model-based simulation of glycaemic control and body weight when switching from semaglutide to 3.0- and 4.5-mg doses of once-weekly dulaglutide.
Tham LS; Pantalone KM; Dungan K; Munir K; Tang CC; Konig M; Kwan AYM
Diabetes Obes Metab; 2022 Feb; 24(2):302-311. PubMed ID: 34697882
[TBL] [Abstract][Full Text] [Related]
2. Improvement of glycaemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 1 study).
Takahashi Y; Nomoto H; Yokoyama H; Takano Y; Nagai S; Tsuzuki A; Cho KY; Miya A; Kameda H; Takeuchi J; Taneda S; Kurihara Y; Atsumi T; Nakamura A; Miyoshi H;
Diabetes Obes Metab; 2023 Jun; 25(6):1503-1511. PubMed ID: 36722623
[TBL] [Abstract][Full Text] [Related]
3. Impact of patient characteristics on efficacy and safety of once-weekly semaglutide versus dulaglutide: SUSTAIN 7
Pratley RE; Aroda VR; Catarig AM; Lingvay I; Lüdemann J; Yildirim E; Viljoen A
BMJ Open; 2020 Nov; 10(11):e037883. PubMed ID: 33199417
[TBL] [Abstract][Full Text] [Related]
4. An Indirect Treatment Comparison of Semaglutide 2.0 mg vs Dulaglutide 3.0 mg and 4.5 mg Using Multilevel Network Meta-regression.
Lingvay I; Bauer R; Baker-Knight J; Lawson J; Pratley R
J Clin Endocrinol Metab; 2022 Apr; 107(5):1461-1469. PubMed ID: 34922383
[TBL] [Abstract][Full Text] [Related]
5. A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK.
Johansen P; Sandberg A; Capehorn M
Adv Ther; 2020 Mar; 37(3):1248-1259. PubMed ID: 32048148
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial.
Yabe D; Nakamura J; Kaneto H; Deenadayalan S; Navarria A; Gislum M; Inagaki N;
Lancet Diabetes Endocrinol; 2020 May; 8(5):392-406. PubMed ID: 32333876
[TBL] [Abstract][Full Text] [Related]
7. Effect of once-weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c.
Gallwitz B; Dagogo-Jack S; Thieu V; Garcia-Perez LE; Pavo I; Yu M; Robertson KE; Zhang N; Giorgino F
Diabetes Obes Metab; 2018 Feb; 20(2):409-418. PubMed ID: 28817231
[TBL] [Abstract][Full Text] [Related]
8. A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA.
Johansen P; Hunt B; Iyer NN; Dang-Tan T; Pollock RF
Adv Ther; 2019 May; 36(5):1190-1199. PubMed ID: 30875029
[TBL] [Abstract][Full Text] [Related]
9. Model-based simulation of glycaemic effect and body weight loss when switching from semaglutide or dulaglutide to once weekly tirzepatide.
Urva S; Levine JA; Schneck K; Tang CC
Curr Med Res Opin; 2024 Apr; 40(4):567-574. PubMed ID: 38407177
[TBL] [Abstract][Full Text] [Related]
10. An indirect treatment comparison of the efficacy of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg.
Pratley RE; Catarig AM; Lingvay I; Viljoen A; Paine A; Lawson J; Chubb B; Gorst-Rasmussen A; Miresashvili N
Diabetes Obes Metab; 2021 Nov; 23(11):2513-2520. PubMed ID: 34286894
[TBL] [Abstract][Full Text] [Related]
11. Relationship between weight change and glycaemic control in patients with type 2 diabetes receiving once-weekly dulaglutide treatment.
Umpierrez GE; Pantalone KM; Kwan AY; Zimmermann AG; Zhang N; Fernández Landó L
Diabetes Obes Metab; 2016 Jun; 18(6):615-22. PubMed ID: 26969812
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ
Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757
[TBL] [Abstract][Full Text] [Related]
13. Lower Drug Cost of Successfully Treating Patients with Type 2 Diabetes to Targets with Once-Weekly Semaglutide versus Once-weekly Dulaglutide in Japan: A Short-Term Cost-Effectiveness Analysis.
Igarashi A; Hunt B; Wilkinson L; Langer J; Pollock RF
Adv Ther; 2020 Oct; 37(10):4446-4457. PubMed ID: 32870471
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of Once-Weekly GLP-1 Receptor Agonist Semaglutide on Glycemic Control in Subjects with Type 2 Diabetes Mellitus: Switching from the Same Class Dulaglutide in a Retrospective Observation Study.
Kimura T; Kubo M; Takahashi K; Wamata R; Iwamoto Y; Iwamoto H; Katakura Y; Sanada J; Fushimi Y; Shimoda M; Tatsumi F; Nakanishi S; Mune T; Kaku K; Kaneto H
J Diabetes Res; 2024; 2024():5880589. PubMed ID: 38223524
[TBL] [Abstract][Full Text] [Related]
15. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.
Pratley RE; Aroda VR; Lingvay I; Lüdemann J; Andreassen C; Navarria A; Viljoen A;
Lancet Diabetes Endocrinol; 2018 Apr; 6(4):275-286. PubMed ID: 29397376
[TBL] [Abstract][Full Text] [Related]
16. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial.
Dungan KM; Povedano ST; Forst T; González JG; Atisso C; Sealls W; Fahrbach JL
Lancet; 2014 Oct; 384(9951):1349-57. PubMed ID: 25018121
[TBL] [Abstract][Full Text] [Related]
17. Glycaemic control, body weight, and safety of tirzepatide versus dulaglutide by baseline glycated haemoglobin level in Japanese patients with type 2 diabetes: A subgroup analysis of the SURPASS J-mono study.
Osonoi T; Oura T; Hirase T
Diabetes Obes Metab; 2024 Jan; 26(1):126-134. PubMed ID: 37794628
[TBL] [Abstract][Full Text] [Related]
18. A 24-week study to evaluate the efficacy and safety of once-weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD-8).
Dungan KM; Weitgasser R; Perez Manghi F; Pintilei E; Fahrbach JL; Jiang HH; Shell J; Robertson KE
Diabetes Obes Metab; 2016 May; 18(5):475-82. PubMed ID: 26799540
[TBL] [Abstract][Full Text] [Related]
19. Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9).
Pozzilli P; Norwood P; Jódar E; Davies MJ; Ivanyi T; Jiang H; Woodward DB; Milicevic Z
Diabetes Obes Metab; 2017 Jul; 19(7):1024-1031. PubMed ID: 28294499
[TBL] [Abstract][Full Text] [Related]
20. Impact on HbA1c and body weight of switching from other GLP-1 receptor agonists to semaglutide: A model-based approach.
Overgaard RV; Lindberg SØ; Thielke D
Diabetes Obes Metab; 2019 Jan; 21(1):43-51. PubMed ID: 30047216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
